ND PHARMA & BIOTECH´S REGENERATIVE STEM CELLS
ND CellexP
ND Pharma & Biotech is a leader in the development of patient-specific multicellular therapies for the treatment of certain diseases from neurological conditions to wound and skin injuries to severe, chronic cardiovascular diseases. Stem cell therapy is the infusion, injection or transplantation of whole cells into a patient for the treatment of a disease or condition.The goal of cell therapy is to repair or restore damaged tissues or organs. One of the most common cell therapies is the use of bone marrow transplantation.
Our scientists and researchers use a proprietary cell processing manufacturing technology to expand naturally occurring populations of cells derived from the patient’s own bone marrow. The bone marrow sample taken from the patient, in the first step of the process, contains a range of cells known to play important roles in the natural healing mechanisms of the human body. Through research and clinical development, it has been shown that ND Pharma & Biotech´s proprietary stem-cell manufacturing process yields a mixture of cell types with diverse properties that promote long-term tissue repair in conditions such as critical limb ischemia and dilated cardiomyopathy—critical cardiovascular diseases that currently have limited or no treatment options. Contact us with questions about our research and development or manufacturing process.
Our scientists and researchers use a proprietary cell processing manufacturing technology to expand naturally occurring populations of cells derived from the patient’s own bone marrow. The bone marrow sample taken from the patient, in the first step of the process, contains a range of cells known to play important roles in the natural healing mechanisms of the human body. Through research and clinical development, it has been shown that ND Pharma & Biotech´s proprietary stem-cell manufacturing process yields a mixture of cell types with diverse properties that promote long-term tissue repair in conditions such as critical limb ischemia and dilated cardiomyopathy—critical cardiovascular diseases that currently have limited or no treatment options. Contact us with questions about our research and development or manufacturing process.
Advantages of Using Patient Bone Marrow & ND Pharma CellexP in Treating Severe and Chronic Diseases.
ND CellexP has several features that are critical for success in treating patients suffering from a complex, multi-factorial, severe and chronic diseases such as critical limb ischemia (CLI), dilated cardiomyopathy (DCM) or certain neurodegenerative diseases (CND´s)
*ND Pharma & Biotech has agreements with a number of institutions and medical centers (both teaching, public & private) worldwide. These centers are not agents of this company, neither ND Pharma & Biotech maintain commercial, business or economic interest within and/or in partnership with such centers and/or institutions. The reference centers are selected and agreed to use ND CellexP system only under strict training and supervision of the physicians and surgeons performing and attending real patients at that centers and locations those centers has in different places and countries, including but not limited to U.S. Mainland and Territories, The U.K. and some Overseas Territories, EU, Latin America and certain Asian countries. For more detailed information, please contact us.
ND CellexP has several features that are critical for success in treating patients suffering from a complex, multi-factorial, severe and chronic diseases such as critical limb ischemia (CLI), dilated cardiomyopathy (DCM) or certain neurodegenerative diseases (CND´s)
- Patient-specific (autologous): We start with the patient’s own cells, which are accepted by the patient’s immune system, allowing the cells to differentiate and integrate into existing tissues. This characteristic of our therapy, we believe, eliminates both the risk of rejection and the risk of having to use immunosuppressive therapy pre- or post-therapy. Our data also suggests that ixmyelocel-T provides the potential for long-term engraftment and repair.
- Expanded: We begin with a small amount of bone marrow from a patient (approximately 50ml) and significantly expand the number of certain cell types, primarily CD90+ mesenchymal cells, CD14+ monocytes and alternatively activated macrophages to far more than are present in the patient’s own bone marrow (up to 300 times the number of these cells compared with the starting bone marrow).
- Multicellular: We believe the multiple cell types in ND CellexP, which are normally found in bone marrow but in different quantities, possess several functions required for tissue remodeling, immuno-modulation and the promotion of angiogenesis.
- Minimally invasive: Our aspiration procedure for taking bone marrow can be performed in an outpatient setting and takes approximately 15 minutes. For diseases such as CLI, the administration of ND CellexP is also performed in an outpatient setting in a single procedure lasting approximately 20 minutes.
- Safe: Bone marrow and bone marrow–like therapies have been used safely and efficaciously in medicine for over three decades. ND CellexP leverages this body of scientific study and medical experience. Further, of the nearly 300 patients who have been treated in recent clinical trials (over 4000 patients safely treated since inception), There appears to be no safety issues and or concerns associated with ND CellexP treatment.
*ND Pharma & Biotech has agreements with a number of institutions and medical centers (both teaching, public & private) worldwide. These centers are not agents of this company, neither ND Pharma & Biotech maintain commercial, business or economic interest within and/or in partnership with such centers and/or institutions. The reference centers are selected and agreed to use ND CellexP system only under strict training and supervision of the physicians and surgeons performing and attending real patients at that centers and locations those centers has in different places and countries, including but not limited to U.S. Mainland and Territories, The U.K. and some Overseas Territories, EU, Latin America and certain Asian countries. For more detailed information, please contact us.
Developing and Delivering Future Therapies Now
Stem Cells are keen to Regenerative Medicine, Personalized Therapies and Immune System-Based Targeted Therapeutics
As Pioneers in the field ND Pharma is compromised with Advance Research and Development within.
______________________
More Info?
Contact Us @: Office of The Chief Scientific
[email protected]
(Ref: Stem cells)
As Pioneers in the field ND Pharma is compromised with Advance Research and Development within.
______________________
More Info?
Contact Us @: Office of The Chief Scientific
[email protected]
(Ref: Stem cells)
